All In Biotech

Drug Trial Radar · NCT07025824

Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

Randomized Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Jan 21, 2026

Primary completion

Sep 2029

Study completion Sep 2029

Sponsor

Lead sponsor
Technische Universität DresdenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
medac GmbH
First posted
Jun 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to compare the effectiveness and tolerability of two conditioning chemotherapies prior to allogeneic stem cell transplantation. The following will also be investigated: * Survival * Remission and Relapse rate * Engraftment or graft failure * Graft versus Host Disease (GvHD)

Conditions

  • AML - Acute Myeloid Leukemia
  • MDS (Myelodysplastic Syndrome)

Interventions

  • Treosulfan (Treo)Drug

    10 g/m2 intravenous

  • Melphalan (Mel)Drug

    140 mg/m2 intravenous

  • Fludarabine (Flud)Drug

    30 mg/m2 intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. overall survival (OS)Time frame: 2 years after randomization

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Universitätsklinikum Aachen, Medizinische Klinik IV

    Aachen, Germany · Recruiting

  • Klinikum Augsburg, Medizinische Klinik II

    Augsburg, Germany · Recruiting

  • Helios Klinikum Berlin Buch, Klinik für Onkologie und Palliativmedizin

    Berlin, Germany · Recruiting

  • Klinikum Chemnitz gGmbH; Klinik für Innere Medizin III

    Chemnitz, Germany · Recruiting

  • Universitätsklinikum Köln, Klinik I für Innere Medizin

    Cologne, Germany · Recruiting

  • Medizinische Fakultät der TU Dresden, Medizinische Klinik und Poliklinik I

    Dresden, Germany · Recruiting

  • Universitätsklinikum Frankfurt, Medizinische Klinik II

    Frankfurt am Main, Germany · Recruiting

  • Universitätsklinikum Greifswald, Klinik und Poliklinik für Innere Medizin C

    Greifswald, Germany · Recruiting

  • Universitätsmedizin Halle (Saale), Klinik für Innere Medizin IV

    Halle, Germany · Recruiting

  • Universitätsklinikum Jena, Klinik für Innere Medizin II

    Jena, Germany · Recruiting

  • Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Innere Medizin II

    Kiel, Germany · Recruiting

  • Universitätsklinikum Leipzig, Klinik und Poliklinik für Hämatologie, Zelltherapie, Hämostaseologie und Infektiologie

    Leipzig, Germany · Recruiting

  • Klinikum der Johannes Gutenberg Universität, III. Medizinische Klinik und Poliklinik

    Mainz, Germany · Not yet recruiting

  • Universitätsklinikum Münster, Medizinische Klinik A, KMT-Zentrum

    Münster, Germany · Recruiting

  • Klinikum Nürnberg, Campus Nord, Klinik für Innere Medizin 5

    Nuremberg, Germany · Recruiting

  • Universitätsklinik Rostock, Klinik und Poliklinik für Innere Medizin, Abt. für Hämatologie/Onkologie

    Rostock, Germany · Recruiting

  • Robert-Bosch-Krankenhaus, Hämatologie, Onkologie und Palliativmedizin

    Stuttgart, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.